Durable Control of Psoriatic Arthritis with Guselkumab Across Domains and Patient Characteristics: Post Hoc Analysis of a Phase 3 study
Clin Rheumatol 2024 doi: 10.1007/s10067-024-06991-8 Epub ahead of print
Ritchlin et al. conducted a post hoc analysis of the DISCOVER-2 trial, evaluating the efficacy of guselkumab in biologic-naïve patients with PsA. Guselkumab provided durable disease control across key PsA domains and PROs over 2 years, regardless of baseline characteristics. A significant proportion of patients achieved stringent endpoints such as ACR50/70, complete skin clearance, and resolution of dactylitis/enthesitis.
The study aimed to assess patterns of stringent disease control with 2 years of guselkumab treatment in biologic-naïve PsA patients, focusing on various PsA domains and PROs in subgroups defined by baseline characteristics. This comprehensive evaluation supports guselkumab as an effective treatment option for diverse PsA patient types, providing consistent and durable disease control across multiple domains.
Keywords:
